Volagidemab
Based on 1 Customer Validation
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D).
For research use only. We do not sell to patients.
- Purity: ≥99.0%
- CAS No.: 1233956-13-2
- Molecular Weight:147.02 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG2 kappa
Human
GCGR
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Alloxan-induced diabetic mice [2]
-
Dosage:5 mg/kg
-
Administration:Subcutaneous injection (s.c.)
-
Result:Reduced phosphorylated CREB protein and PEPCK protein expression to nondiabetic levels.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1233956-13-2
-
Appearance Liquid
-
Molecular Weight 147.02 kDa
-
Color Colorless to light yellow
-
SMILES
[Volagidemab]
-
Synonyms
REMD-477; AMG-477
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Pettus J, et al. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med. 2022 Oct;28(10):2092-2099. [Content Brief]
[2]. Wang MY, et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2503-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Volagidemab Related Classifications
HY-P99383 Related Classifications
Powered by Bioz